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ABSTRACT
Drug-related deaths have increased significantly in Scotland in recent years, with a much greater per-
centage increase in deaths among women than among men. We undertook a mixed-methods project
to identify explanations for this trend, comprising three parallel methodological strands: (i) an analysis
of available routine data, including drug treatment data, death registrations, and surveys of people
using needle exchanges; (ii) thematic analysis of interviews and focus groups with professional stake-
holders and (iii) secondary analysis of interviews with women who use drugs. Results indicated that
the observed trend is likely to reflect multiple, interacting causes. Potential contributors identified
were: ageing; changing patterns of substance use; increasing prevalence of physical and mental health
co-morbidities; changing relationships and parenting roles; changes to treatment services and wider
health and social care provision; unintended consequences or poor implementation of recovery-ori-
ented practice; and changes in the social security system. Policy responses to rising drug-related death
rates require a gender-informed approach, recognising the commonalities and differences between
men and women who use drugs; the diversity of experiences within each gender; and the intersections
between gender and other forms of inequality, such as poverty.
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Introduction
Drug-related deaths (DRD) have been increasing in Scotland
in recent years (National Records of Scotland, 2019b). In
2018, 1,187 deaths were registered—the highest number
ever recorded and a 107% increase on 2008. Although men
account for the majority of DRD, the percentage of women
has increased over time, from 19% in 2004–2008 to 29% in
2014–2018. When comparing the annual averages for these
two periods, the percentage increase in the number of DRDs
was greater for women (212%) than for men (75%). Figure 1
shows the overall trend in number of deaths by gender.
A number of explanations have been proposed for the
overall increase in DRD observed throughout the UK and a
number of other high-income countries, including a prema-
turely ageing cohort of people who use opioids; a rebound
in heroin availability in recent years; polysubstance use; phys-
ical and mental health co-morbidities; worsening socioeco-
nomic circumstances; and changes in drug treatment
provision (Advisory Council on the Misuse of Drugs, 2016).
However, to date there has been limited consideration of the
reasons why current trends in DRD differ by gender.
Cohort studies of people who use drugs consistently find
a higher crude or absolute DRD rate among men compared
to women (Mathers et al., 2013). The reasons for this observa-
tion are uncertain. While there are many commonalities
between men and women who use drugs, there are several
areas where experiences of substance use, harm reduction,
and treatment differ in ways that may affect drug-related
death risk. For instance, women appear to experience greater
stigma associated with drug use, related to societal gender
roles and expectations, and unique barriers to accessing
treatment services (European Monitoring Centre for Drugs &
Drug Addiction, 2017). There is also some evidence that
women are more likely to engage in non-medical use of pre-
scription drugs, though this may reflect greater exposure to
prescription medications with the potential for abuse
(Clark, 2015).
Among opioid users, men are more likely to inject and to
experience episodes of imprisonment (Bird et al., 2003;
European Monitoring Centre for Drugs & Drug Addiction,
2006; Shand et al., 2011), both of which are important risk
factors for DRD, though studies from the National Drug
Treatment Monitoring System in England have found that
these factors only partly explain the observed difference in
mortality risk (Pierce et al., 2016, 2018).
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There is also some evidence that the impact of known risk
factors varies between men and women. Increasing age is an
important risk factor for DRD, but this effect appears to be
especially pronounced among women (Onyeka et al., 2014;
Pierce et al., 2015, 2016). There is also uncertainty about dif-
ferential impacts of treatment: one cohort study from
England found that women were less at risk of DRD during
out-of-treatment episodes than men (Pierce et al., 2016),
while others have found that, unlike deaths in which heroin
only is implicated, rates of methadone-specific mortality are
similar (Gao et al., 2016; Pierce et al., 2018). The extent to
which these observations are due to physiological differences
between the sexes versus gender inequalities in social experi-
ence remains uncertain, though direct evidence for the for-
mer appears to be limited (European Monitoring Centre for
Drugs & Drug Addiction, 2017).
In light of recent trends, and evidence of important differ-
ences in the experience and vulnerability of women and men
who use drugs, we undertook a mixed-methods examination
of potential explanations for the rising rate of DRDs among
women in Scotland in recent years.
Methods
Definition of DRD
In Scotland, DRDs are reported annually by National Records
of Scotland (NRS) according to a standardised definition
(National Records of Scotland, 2019b). In Scotland, there is a
legal requirement to register deaths within 8 days, therefore
there is a high level of correspondence between the year of
registration of death (used by NRS for reporting) and year
of death.
Analysis of routine data
Routine national data about people accessing drug treatment
services or experiencing drug-related harms were obtained
from the sources described in Table 1, either from existing
publications or bespoke requests. All data obtained via
bespoke requests were provided in aggregate form to pro-
tect confidentiality.
Stakeholder views
Views were sought from key professional stakeholders from
statutory services, the third sector, and academia, as part of
an information gathering exercise to generate and explore
hypotheses for the observed trends. Stakeholders were
recruited by invitations sent through existing networks
including the Partnership for Action on Drugs in Scotland
Harm Reduction Group (a stakeholder group convened by
Scottish Government to inform drug policy) and local Alcohol
and Drug Partnerships (responsible for the provision and
commissioning of local alcohol and drug services in
Scotland), as well as professional contacts of the authors.
Potential participants were provided with an information
sheet and invited to participate by email. Verbal informed
consent to participate was obtained and documented at the
start of the interview.
Informal semi-structured interviews (in person or by tele-
phone) and focus groups were undertaken by RM and EJT,
with fieldnotes taken during and immediately after the event.
As these interviews and focus groups were recorded via field
notes rather than audio recordings, no direct quotations are
included in this report.
In all, we undertook 15 individual interviews; one joint
interview with two participants; two focus groups; and one
observed meeting of an existing community of practice. A
summary of stakeholder roles is provided in Supplementary
Material and an example topic guide is available on request.
Secondary analysis of interviews with women who
use drugs
To incorporate insights from women with lived experience of
drug use without imposing additional research burden on
them, we undertook secondary analysis of interviews con-
ducted as part of the Older People with Drug Problems
(OPDP) project. The methods of the OPDP project, which
Figure 1. Number of drug-related deaths in Scotland 1996–2018, by gender. Source: National Records of Scotland.
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recruited women from a range of non-NHS settings across
Scotland such as needle exchanges, voluntary organisations,
and homelessness services, are described elsewhere
(Matheson et al., 2019). Interview data were anonymized and
analysis conducted by the researcher who undertook the
interviews (CM).
For this project, 13 additional interviews were transcribed
and used alongside 15 existing transcripts, resulting in a sam-
ple of interviews with 28 women.
Analysis
Routine national data sources were analysed descriptively.
Qualitative data was coded using directed content analysis
collaboratively by RM, EJT, and CM, based on a thematic
matrix reflecting potential explanations which was developed
iteratively in response to emerging findings and themes.
During this process, representative quotations were identified
for inclusion in the paper to illustrate key themes. A copy of
the thematic matrix is available on request. The results of the
quantitative and qualitative analyses were combined through
a narrative synthesis organised according to the key emerg-
ing hypotheses. Reflecting the mixed-methods approach of
the study and its goal of developing an explanatory frame-
work, the rest of the paper presents a findings section which
integrates results and interpretation, followed by key conclu-
sions and implications for policy and practice (Bazeley, 2015).
Ethical approval
The project was conducted in accordance with the Scottish
Government Social Research Ethics Guidance.
Terminology
Despite the distinct meanings of the terms sex and gender,
they were often used interchangeably and inconsistently in
Table 1. Routine data sources used in the study.
Name Source of data Responsible organisation More information
Death registrations National death registration data. As well as deaths
classified by ICD codes as drug-related, all deaths
where information on the death certificate is
vague or suggests drugs may be implicated are
followed up to ascertain whether they may be
drug-related. A dedicated questionnaire is










Local DRD co-ordinators collect detailed information
on the nature of DRDS and the health and social
circumstances of individuals involved, using
records from primary and secondary health care,
drug treatment services, social work, police and
prisons. The NDRDD is also routinely linked to












Completion of a standard national dataset for people
assessed by specialist drug treatment servicesa.
Includes demographic information, prescribed and
illicit drug profile, injecting risk behavior, social











Routine administrative data on hospital admissions
associated with drug use from acute inpatient
and day case hospital admissions (SMR01 records)












Cross-sectional biobehavioural survey of people who
inject drugs with a focus on injecting risk
behaviours and blood-borne virus prevalence.
Participants recruited from selected agencies and








Prevalence of problem drug
use in Scotland
Successive studies undertaken every three years
since 2000 have estimated the prevalence of
problem drug use among those aged 15–64 years
living in Scotland. For the purposes of the report,
problem drug use is defined as the problematic
use of opioids (including illicit and prescribed
methadone use) and/or the illicit use of
benzodiazepines, and implies routine and
prolonged use as opposed to recreational and
occasional drug use. Estimates are derived from
capture-recapture methods using data from












a‘Initial assessments’ in the Scottish Drugs Misuse Database (SDMD) refer to episodes of individuals first making contact with services providing tier 3 and 4 inter-
ventions (i.e. structured community or residential drug treatment) or reinitiating contact following a gap of at least six months since last attendance. Services
contributing to the SDMD include specialist drug services and some medical services.
DRUGS: EDUCATION, PREVENTION AND POLICY 3
our sources. Our intention with this work was to present an
account of what might contribute to the disproportionate
upward trend in DRD among women, rather than undertak-
ing a detailed analysis of the gendered nature of drug use or
the relative contribution of sex and gender differences. For
simplicity, we therefore use the terms women/men and gen-
der throughout this article, though we continue to use
female/male as adjectives.
Findings
This narrative summary of the evidence examined draws on
the synthesis of all methodological strands, reflecting the
challenges inherent to our topic: up-to-date evidence on rele-
vant factors in recent years is limited; what is available does
not lend itself to formal hypothesis testing; and in reality the
causes of this phenomenon are likely to be multiple and
interacting.
Explanations are ordered by theme, rather than import-
ance; starting with potential changes in the measurement of
DRD that may have created the erroneous impression of a
trend, before moving on to consider explanations relating to
individual factors, communities and services, and soci-
etal trends.
Changes in the definition and recording of DRD
Analysis of National Records of Scotland (NRS) data show
that the trend in DRDs among women was not substantially
affected by changes in the legal classification of drugs since
2000 (Table S2.1, Supplementary Material): the number of
deaths excluded from the standard DRD figures because the
substance involved was not controlled at the time of death
were relatively small in number across the time series and
were not higher among women. Moreover, although there
are a number of artefactual factors which may affect trends
in DRD rates over time and place (such as advances or
changes in toxicology testing or practice), these are unlikely
to differ by gender. Changes in the definition or recording of
DRD are therefore unlikely to explain the trends observed.
Changes in the population at risk
Understanding the scale of problem drug use—particularly
over time—is challenging: this section therefore triangulates
a number of data sources to investigate the potential contri-
bution of changes in the population at risk. Table S2.2
(Supplementary Material) summarises evidence from commu-
nity and treatment-based data sources, which suggest a
largely stable gender profile among a static or falling popula-
tion of people who use drugs or with drug problems in
Scotland. The limited data available on duration of injecting
drug use also suggest that this is unlikely to explain the dif-
ferential trends by gender.
However, given the limitations of self-report or treatment
data, they do not completely exclude the possibility of
‘hidden’ populations of people who use drugs (particularly
prescribed drugs) which may be growing in number and/or
experiencing increased risk of DRD.
Analysis of data from the National Drug-Related Deaths
Database (NDRDD) found that the percentage of female
decedents who were known to use drugs decreased over
time from 90% in 2009 to 81% in 2016, whilst among men it
has remained largely stable, at 89% and 91% respectively
(Information Services Division Scotland, 2018a). In keeping
with this, several professional stakeholders raised concerns
about local examples of DRDs associated with prescription
drugs (such as opioid painkillers and benzodiazepines)
among older women not fitting the typical profile of people
considered to be at risk.
In addition, the Older People with Drug Problems in
Scotland (OPDP) project identified a group of people using
benzodiazepines problematically, but not using opioids:
women aged 35 or over were more prevalent among this
group than among the overall cohort used for the project
(Scottish Drugs Forum, 2017). A very high percentage of
these women did not have any specialist drug treatment or
drug-related hospital activity during the study period.
However, mortality among those using benzodiazepines only
in the OPDP project was much lower than for those with opi-
oid use (2.3% vs 4.2%) so a hidden population of women
using benzodiazepines appears unlikely to explain a higher
relative increase in DRD.
In keeping with this, other stakeholders had not observed
any such trend locally and the vast majority of DRDs con-
tinue to involve illicit opioids. This possibility is therefore
unlikely to make a major contribution to the overall trend
but may warrant further investigation.
Together the results in Table S2.2 suggest that the higher
relative increase in DRDs among women compared to men is
unlikely to be driven by an increase in the number of women
using drugs or in their relative duration of exposure to drug-
related risks.
Ageing among women who use drugs
Routine data sources (supplementary Table S2.2) suggest that
the median age of both women and men who use drugs in
Scotland is increasing, with similar trends by gender over
time. This is also the case for people experiencing DRD.
Among people accessing IEP services and treatment, the
median age is slightly higher among men, but among people
who died, the reverse is true although this difference is small.
These data suggest that ageing alone cannot explain the dis-
proportionate increase in DRD among women.
DRD rates per estimated 1000 problem drug users have
increased or remained largely stable within the three age
strata for which data are available (Figure 2); the picture is
similar when considering DRD rates per 1000 total popula-
tion, for which ten-year age strata are available (National
Records of Scotland, 2019b).
It is also important to examine why age is associated with
an increase in the risk of DRD, and whether this effect may
vary by gender. It is unclear to what extent age exerts a dir-
ect causal effect on DRD risk (for example, through a greater
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burden of physical co-morbidities) or is a marker for other
risk factors (such as poly-substance use, social isolation, or
more complex life circumstances). Stakeholder interviews
identified age as a factor that needed to be critically interro-
gated, arguing that it was important to understand the activ-
ities and experiences of people who use drugs as they age.
For instance, as described in the subsequent section on
‘Relationships’, increasing age appears to be associated with
increasing social isolation, and with greater reflections on
one’s life stage and circumstances. These themes are illus-
trated by the quotations below from interviews with women
who use drugs.
I think it’s got quite a lot to do with mental health, but
sometimes I don’t know, I just, I’ve given up just now, because
everybody’s been dying round about me, just giving up.
…now that I’m 35 I’m thinking “Oh my God, I’m nearly hitting
40, I’m still using gear, I haven’t got a job, a lot of mental illness,
I haven’t got any kids, I’m not married. My Mum and Dad wanted
more for me than that and I feel, they make me feel guilty about
that you know.
Ageing effects (the result of growing older) are difficult to
separate from cohort effects (the result of being born during
a specific period) and period effects (the result of factors that
occur at a particular time and affect all age groups equally).
A recent analysis of time trends to disentangle these factors
in drug-related death risk in Scotland, found that as well as
ageing, a cohort effect associated with an increase in risk
among those born between 1960 and 1980 was present
among women but less pronounced than among men
(Parkinson et al., 2018).
Age may therefore be important not only as a cause of
physical vulnerability but also as a marker of wider life
changes and transitions as well as historical experiences.
Many of these age-related factors—whether physical, mental,
or social—are potentially amenable to intervention
and support.
Changing patterns of drug use among women
Data sources on drug use suggest similar trends in men and
women in recent years. Scottish Drug Misuse Database
(SDMD) data show that opioids remain the most common
drug class for which people undergoing initial assessment in
specialist drug services seek help, with little difference
between genders (Figure 3). With regard to other drug
classes, recent years saw substantial increases in men seeking
Figure 2. Rates of drug-related death per estimated 1000 problem drug users, by gender and age group.
Source: National Records of Scotland & Public Health Scotland.
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help where the main illicit drug was cocaine or gabapenti-
noids, outstripping smaller increases among women.
Looking at results from the Needle Exchange Surveillance
Initiative (NESI) among people attending injecting equipment
provision services, a similarly high percentage of both gen-
ders reported injecting heroin in the last 6 months (92%
women vs 90% men). Both genders showed a substantial
upwards trend in injecting cocaine and crack in recent years,
though women remained less likely than men to inject these
(either alone or in combination with heroin). Trends in inject-
ing benzodiazepines and ‘legal highs’ (i.e. novel psychoactive
substances) were similar by gender.
Among drugs implicated in or potentially contributing to
deaths, opiates remain the most common drug in both gen-
ders, though benzodiazepines and cocaine have shown rapid
increases in recent years (Figure 4) (National Records of
Scotland, 2019a). Trends in deaths relating to these drugs
were generally more pronounced among men, except for
alcohol, where the picture was similar among men and
women. NRS data on decedents indicates that the percent-
age of deaths in which alcohol is implicated has declined
among women since 2000 (data not shown), suggesting
changes in alcohol consumption are unlikely to explain the
observed trends. The percentage of deaths in which any opi-
ate was implicated remained largely stable in both genders
over time: among women, the percentage of deaths involv-
ing methadone has in most years been slightly higher than
among men, and the percentage of deaths involving heroin/
morphine slightly lower (data not shown). This is consistent
with recent findings that a higher percentage of women who
inject drugs (NESI)—and women who die from DRDs
(NDRDD)—receive prescribed methadone than men though
this does not preclude higher rates of illicit methadone use
or a greater physical susceptibility to complications of
Figure 3. Number of individuals presenting for initial assessment in specialist drug services between 2006–2007 and 2017–2018, by financial year, gender, and
main type of illicit drug. (Note different scales of Y axis). Note that data quality issues mean that data for 2012–2013 and 2013–2014 are not available.
Source: Scottish Drug Misuse Database, Public Health Scotland.
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methadone treatment. The number and percentage of deaths
in which methadone is implicated has increased in recent
years, and declined for heroin, though both trends are similar
between genders (National Records of Scotland, 2019a).
NRS data show that multiple drugs are present in the
body at time of death for almost all DRD in Scotland, with
the majority having multiple substances implicated (National
Records of Scotland, 2019b). Although previously, the per-
centage of deaths in which multiple drugs (and, perhaps,
alcohol) were implicated was higher among women, in more
recent years trends for the two genders have converged
(supplementary Figure S4.1). For most combinations, the dir-
ection of the trend over time was similar for both genders or
steeper among men. The only apparent exception to this was
deaths where methadone and alcohol (with or without other
drugs) were implicated, where the trend appeared to be
slightly steeper among women, though this was a relatively
uncommon combination and total numbers were still higher
among men (National Records of Scotland, 2019a).
The Office for National Statistics (ONS) ‘wide’ definition for
DRD can be used to examine deaths in which prescribable
drugs are implicated, since it counts all deaths from drug
poisoning regardless of whether a drug listed under the UK
Misuse of Drugs Act (1971) was known to be present in the
body at the time of death (National Records of Scotland,
2019b). Death registration data using the ONS wide definition
suggest a much smaller gender gap than for illicit drugs
(Figure 5), with an especially marked rise in deaths involving
gabapentinoids in both genders in recent years. Both gen-
ders have also seen gradual upward trends in the number of
deaths with anti-depressants involved, with these consistently
involved in a higher percentage of deaths among women
than men. For anti-psychotics, although there is an apparent
upward trend in recent years, the numbers are much smaller
and there is no consistent gender difference.
From stakeholder interviews, prescription drugs were iden-
tified as a potential factor in the observed trend in DRDs
among women. This includes both the problem use of pre-
scription drugs by women without a history of dependence
on other drugs and who do not fit the conventional profile
of people at risk of drug-related harms (as discussed above
under ‘Changes in the size of the population at risk’), as well
as prescription drug use among women with established
street drug use. Drugs identified as particular concerns
include gabapentinoids and benzodiazepines, especially
short-acting formulations (e.g. alprazolam). Some stakehold-
ers identified that women were more likely to be prescribed
drugs with the potential for abuse such as these, though
illicit supply was also recognised as an important source. One
stakeholder suggested that prescription drugs—not detected
on urine screening—may be particularly appealing to women
going through child protection proceedings.
Polysubstance use (of illicit or prescribed drugs, or—most
commonly—both) was felt by stakeholders to be particularly
problematic with increasing age, due to a loss of physio-
logical reserve and greater prevalence of co-morbidities. It is
Figure 4. Number of deaths where opiates, benzodiazepines, cocaine, or alcohol were implicated in, or potentially contributed to, the cause of death, by gender:
NRS definition. (Note different scales of Y axis).
Source: National Records of Scotland. NRS definition of drug-related death, based on UK Drug Strategy. These data will therefore not include deaths involving any substances uncontrolled
at the time of death (e.g. an overdose of tramadol alone prior to 10 June 2014 or an overdose of etizolam prior to 31 May 2017). The dashed line delineates a change in reporting practice
for drugs involved: up to 2007, some pathologists reported only those drugs which they thought directly contributed to the death, whereas from 2008, they report separately drugs which
were implicated in, or which potentially contributed to the death (shown here), and those which were present, but were not considered to have contributed to the death (not shown
here). Since these data record individual mentions of particular drugs, there will be multiple-counting of deaths where more than one drug is present.
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unclear whether gender differences in harms might reflect
differences in the prevalence of polydrug use or in vulner-
ability to its effects. Further work to investigate polysub-
stance use from routine data sources—such as SDMD and
death registrations—is an important area for future work.
Changes in relationships and parenting roles
The link between women having children removed from their
care and risk of DRD was a recurring theme with professional
stakeholders and women with lived experience. Stakeholders
described how, with increasing age, women may have experi-
enced multiple child removals, may have very limited positive
family relationships, and may find the prospect of declining
fertility in this context difficult. Some felt these factors were
contributing to retraumatisation, hopelessness and risky con-
sumption among women, increasing the risk of DRD. This
was supported by women who use drugs’ accounts of their
experiences of child protection proceedings:
Well my last time I was clean I got, I came down, got reduced
and I came off it, and it wasna [wasn’t] until I got my children
taken away from me last year that I went back.
I mean I think I would have stopped wi’ the methadone if there
hadn’t been so many up and downs with the children getting
taken off me and such, and there’s been so much, and then, I
went through. My kids got taken off me, beatings from the ex, so,
Women’s Aid people were involved, come up to talk to me,
things like that. So there had been a lot of things that, not made
me take drugs but, I chose to take them to help. But then it
doesn’t help. It doesn’t seem to force away the things from
your head.
On the other hand, one professional stakeholder sug-
gested that without the risk of pregnancy and fear of child
protection concerns, older women may be more able to
engage with treatment services.
There are few routine data on the role of relationships
and parenting in DRD. Data from NDRDD show that the per-
centage of women who died who were parents or parental
figures increased between 2009 and 2011 and subsequently
declined. However, there was no clear trend in the percent-
age of women who died who were living with children under
16 years at the time of death (Figure S2.2 in Supplementary
Material). Among men who died, both measures have been
relatively stable over time. No trend data on child protection
social work activity where drugs were a factor were available
for this report. This merits further investigation.
Regarding relationships more generally, increasing social
isolation was identified as a growing problem by a number
of stakeholders and by women themselves. Causes cited
included deaths within peer groups, relationship breakdown
with non-using friends and family among people who con-
tinue to use, the end of friendships with drug-using peers
among people entering treatment and recovery, mental
health problems, or a lack of trust in others following trauma.
Some of these themes are illustrated by the quotations
below from interviews with women who use drugs:
So I needed [name], because my mum wasn’t well, because
obviously I’ve cut everybody out of my life that I did, anybody I
knew that was all to do with drugs.
… me and my mum are so alike, I couldn’t stay with my mum,
because I stayed there for a wee while, but in the end, we end
up fighting, and it’s the same with my sister, my dad, he’s only
like got one room, so that’s no good, and he’s not talking to me
at the minute, because of my sister, so I feel like I’ve just got
nobody really
These factors may be particularly salient for women, given
the evidence that women’s drug use tends to be more
closely linked to intimate relationships and is more highly
stigmatized. Some stakeholders also highlighted a lack of
gender-concordant peer support for women within existing
services. On the other hand, there is some evidence to sug-
gest that women are more able to establish new social rela-
tionships unrelated to drug use than men, and enjoy a
greater level of practical and emotional support from family
members (Neale, 2004).
Experience of adversity, trauma, and violence
The only source of routine data available on this topic in
Scotland is the National Drugs-Related Deaths Database,
which collects information on whether the decedent was
known to have been a victim of domestic violence or sexual
abuse. Among those dying between 2009 and 2016, both of
these experiences were much more common among women
than men (overall prevalence 44% vs 5%) but there were no
clear trends over time observed in either gender (Information
Services Division Scotland, 2018a).
Stakeholders, however, did identify some potential factors
which have changed in recent years which may interact with
women’s experiences of adversity, trauma, and violence to
increase the risk of drug-related harms, including death.
These include:
 Changes in the social security system which make
women more vulnerable within relationships. For
instance, the new Universal Credit payment is claimed as
a household but only paid to one individual, which may
reduce women’s economic independence, as may the
increased use of sanctions (Engender, 2015; Scottish
Government, 2013).
 Life events or transitions more common among an age-
ing cohort, such as bereavements, multiple child remov-
als, and loss of fertility, which may be traumatic in
themselves and compound the effects of previ-
ous trauma.
 Changes to health and social services resulting in
reduced provision (e.g. mental health), a lack of continu-
ity (whether in services themselves or in staffing), or a
less holistic approach (e.g. as a result of reduced staffing
and skills within addictions services or more ‘punitive’
approaches). These changes may disproportionately
affect engagement and outcomes among people with a
history of trauma, who can experience particular difficul-
ties in accessing services or establishing therapeutic rela-
tionships (Elliott et al., 2005).
Further in-depth work to explore the contributions of
these factors would be beneficial.
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Co-occurring physical and mental health conditions
As described above, increasing prevalence of concurrent
physical and mental health conditions may be one of the
mechanisms linking ageing among people who use drugs
and the recent increase in DRDs (Scottish Drugs
Forum, 2017).
Data from NDRDD suggest that women who died from
DRD had poorer physical and mental health than their male
counterparts, with a somewhat higher prevalence of physical
and mental health conditions, long-term illness or disability,
and recent acute hospital stays. Though the prevalence of
concurrent physical health conditions increased among both
men and women between 2009 and 2016, this increase
appeared to be more marked among women (Information
Services Division Scotland, 2018a). This is substantiated by
figures from SDMD, which suggest that the prevalence of co-
occurring health conditions among people attending treat-
ment services for initial assessment has increased over the
last decade and to a greater extent among women than
men, particularly for mental health issues (Information
Services Division Scotland, 2019).
The Older People with Drug Problems project in Scotland
found that older women had substantially higher rates of
hospitalisation for asthma/chronic obstructive pulmonary dis-
ease, lung cancer, and depression compared to their male
peers, and compared to women in the rest of the population,
whereas older men with drug problems tended to have
higher rates of hepatitis C, liver disease, psychosis and heart
disease (Scottish Drugs Forum, 2017). This suggests that co-
morbidity varies in complex ways with gender and with age,
and points to some factors that may contribute to differential
risk of drug-related death (for instance, poorer lung health
among women).
These data should be interpreted with a number of cav-
eats: for instance, women in the general population tend to
have a higher prevalence of poor physical and mental health
compared to men (Cheong et al., 2018; Scottish Public Health
Observatory, 2020), and there are limited data from sources
other than treatment services or death registrations.
However, together they do suggest a greater increase in the
prevalence of concurrent physical and mental health condi-
tions among women who use drugs than their male peers,
which may be contributing to increases in DRD.
In interviews with women who use drugs, many men-
tioned co-existing mental and physical health problems,
which were often reported to be untreated or under-treated.
These may have a direct impact on overdose risk, for
instance, reduced lung function in the case of respira-
tory disease:
My partner, he’s saying to me, I think I’ve got that COPD [chronic
obstructive pulmonary disease] or something, at night, it’s all
bubbling and he said, he says it’s really scary, but, and I know I
am, I get out of breath so easy, and it’s just wheezing…
Because I’m no getting any sleep, so it’s making me moody and
it’s making me exhausted, moody, eh, [puff out of air], it’s starting
to make my depression worse, because I’m nae [not] getting nae
[any] blooming help because o’ the stigma, probably the doctors
Figure 5. Number of drug-related deaths involving selected prescription drugs, by gender: ONS ‘wide’ definition.
Source: National Records of Scotland. The ONS ‘wide’ definition includes all deaths coded to accidental poisoning, and to intentional self-poisoning by drugs, medicaments and biological
substances, whether or not a drug listed under the Misuse of Drugs Act was present in the body . The dashed line delineates a change in reporting practice for drugs involved: up to 2007,
some pathologists reported only those drugs which they thought directly contributed to the death, whereas from 2008, they report separately drugs which were implicated in, or which
potentially contributed to the death (shown here), and those which were present, but were not considered to have contributed to the death (not shown here). More than one drug may
be reported per death. These are mentions of each drug, so do not add up to the overall total.
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just looked at me and knowing I was an ex-addict, just looked
and when ach, ken [know] what I mean, just gie [give] her that.
Poor mental health and a sense of hopelessness among
women who use drugs was identified as an important factor
by several professional stakeholders. This was felt to increase
the risk of DRD, either directly by increasing the risk of delib-
erate (or ambivalent) overdose, or indirectly, by precipitating
more risky consumption patterns. Several precipitating factors
were described, including loss of access to children, bereave-
ment, and changes to social security arrangements; interview-
ees also identified a reciprocal relationship between social
isolation and mental health. The quotation below, in which a
woman with lived experience describes her current mental
state, illustrates a number of these themes:
Aye, sorry, I think it’s just one of them weeks, I used to sit for
days and shut myself away for days, before I had the youngest
two, but oh god that just gives [father of child] ammunition to
take the bairns [children] off me, and oh god, I don’t want to lose
the bairns again, so I was if I could just make it to the end of the
day, and get to my bed, tomorrow will be a new day, but at
times like now, I just think tomorrow is never coming, sorry.
Although NRS data indicate that deaths by suicide
account for a greater percentage of DRD among women
than men, the overall percentage of DRDs attributed to
intentional self-poisoning among women is largely static or
declining in recent years, reflecting a small increase in abso-
lute numbers outstripped by a much greater rise in deaths
attributable to accidental poisoning (supplementary Table
S2.3). This suggests that the overall increase in DRD among
women is unlikely to be driven by deaths by suicide,
although it can be difficult to ascertain intentionality given
that ambivalence of intention is common among people at
risk of, or who have survived, overdose (Neale, 2000).
Access to and engagement with treatment and harm
reduction services
Both the total number and percentage of female clients
undergoing initial assessment for specialist drug treatment
have remained relatively stable over the past ten years in
Scotland, with women accounting for a similar percentage of
people identified from treatment settings compared to com-
munity-based surveys or figures on drug-related harms (sup-
plementary Table S2).
Data from NDRDD found that between 2009 and 2016, a
greater percentage of female than male decedents had:
 Been in contact with drug treatment services in the six
months prior to death (53% vs 45%)
 Been prescribed opioid replacement therapy at the time
of death (40% vs 27%)
 Experienced previous overdose (59% vs 49%)
Similarly, NESI found that women attending injecting
equipment provision outlets were more likely to have been
prescribed methadone in the last 6 months than men (82%
vs 75% overall for the six sweeps between 2008/2009 and
2017/2018), indicating ongoing street drug use despite opi-
oid replacement therapy .
These data suggest that women may be equally or more
likely to access drug treatment services: the problem there-
fore may lie more with unmet needs or missed opportunities
to intervene.
The interviews with women with lived experience identi-
fied several issues in this regard, including disagreements
with providers about the appropriate dose and duration of
opioid replacement therapy and a perceived lack of capacity
and time, as illustrated below:
I’m only 20ml at [name], and they’ll no budge and put my
methadone up, even though I went back onto heroin for a year,
there’s still expecting me to get off the heroin, giving me 20ml of
meth, which is impossible, you know, I just can’t do it.
Every time I asked them to drop me down, they wouldn’t drop
me down, they kept telling me it was too early, but I knew I was
ready to get dropped down, you know.
Conversely, some interviewees described positive experi-
ences with services and support groups, though lack of
awareness or misunderstandings about eligibility were cited
as a barrier.
Professional stakeholders highlighted the potential impact
of recent cuts to local drug treatment services, resulting in
the closure of gender-sensitive services, higher thresholds for
support, and reductions in staff pay, skill mix, and experience.
Concerns were also raised by some stakeholders about reduc-
tions in provision of allied services which support people
with drug problems, such as education, training, and employ-
ability. Lack of access to these, either due to service cuts or
funding restrictions (e.g. lack of funds to cover travel
expenses), were felt to hinder women’s efforts to achieve sus-
tained reductions or cessation in drug use. This is consistent
with recent reports by Public Health England and the
Advisory Council on the Misuse of Drugs, which suggested
that changes in drug treatment services in England may have
been a contributory factor to rising DRD rates (Advisory
Council on the Misuse of Drugs, 2016; Public Health
England, 2017).
Some stakeholders raised the issue of gaps in harm reduc-
tion provision and potential unintended consequences of
recovery-oriented approaches, such as a drive to reduce or
cease opioid replacement therapy: this was also a theme
identified in the Advisory Council on Misuse of Drugs and
Public Health England reports (Advisory Council on the
Misuse of Drugs, 2016). Some felt that women might be
more vulnerable to the potential risks of a recovery-oriented
treatment system, due to the greater salience of stigma and
child protection concerns, and relational factors influenced
by previous trauma.
With regard to harm reduction, the main source of infor-
mation is naloxone supply and utilisation. Trends between
2008–2009 and 2017–2018 in the percentage of NESI survey
participants reporting having been prescribed or carrying
take-home naloxone (THN) were very similar by gender. As
described in the subsequent section, naloxone uptake among
female prisoners on release is relatively high. NDRDD analy-
ses found that between 2009 and 2016, women who died
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were more likely than men have been in the same room as
another individual at the time of death (42% vs 31%, among
those for whom data were available), though rates of nalox-
one availability were similar, and the percentage of cases
where available naloxone was administered was slightly
higher among women (Information Services Division
Scotland, 2018b). This suggests missed opportunities for
naloxone use in overdoses occurring in both men and
women, though there may be other variations in overdose
response by gender that these data do not capture.
Experiences of prison and re-settlement
Imprisonment was generally recognised by professional
stakeholders as a difficult and disruptive event for women
who use drugs, often accompanied by the loss of child cus-
tody, relationship breakdown, housing difficulties, and deteri-
orations in mental health. Problems experienced by women
in the criminal justice system were mentioned by a number
of stakeholders, including interruption to opioid replacement
therapy on entry to prison and lack of throughcare support
for issues like drug treatment, housing, and relationships.
Data from NDRDD shows that, during the period
2009–2016, female decedents were less likely than their male
counterparts to have been in prison in the last 6 months (7%
vs 17%) or ever in their lives (31% vs 57%), with no clear
trend over time in either gender in the prevalence of prior
imprisonment (Information Services Division Scotland, 2018b).
This is largely consistent with the characteristics of the prison
population in Scotland during this period (Scottish
Government, 2020).
Prisons in Scotland appear to be performing relatively well
with regard to women’s uptake of take-home naloxone at
the point of release (Information Services Division Scotland,
2018c). However, whether this observation impacts on DRDs
will depend on many other factors, including the likelihood
of kits being carried and used, and of overdoses occurring in
the presence of others.
Economic and social trends, including austerity and
welfare reform
There is increasing evidence that the health and social
impacts of recent economic trends and austerity policies dif-
fer by gender (Engender, 2015; Glonti et al., 2015; Scottish
Government, 2013; Thomson et al., 2018). For instance,
women are more reliant on social security than men; are
more likely to be lone parents or unpaid carers; and have
borne a greater burden of recent cuts in social security provi-
sion and funding to public services (Engender, 2015; Scottish
Government, 2013). Research from the Welfare Conditionality
project has highlighted how the current social security sys-
tem is poorly equipped to meet the needs of drug and/or
mental health problems, with the increasing use of condition-
ality particularly harmful (Welfare Conditionality Project,
2018). Welfare reform and austerity have been identified as
potential contributors to rising DRD rates in the UK in recent
reports from national agencies (Advisory Council on the
Misuse of Drugs, 2016; Public Health England, 2017).
This evidence was echoed by professional stakeholders,
who highlighted that women who use drugs often experi-
ence an intersection of structural factors which may heighten
vulnerability to the adverse impacts of austerity and welfare
reform. Some were concerned that by reducing women’s
income and financial autonomy, changes to the benefits sys-
tem may have increased women’s vulnerability to abusive
relationships, sexual exploitation, or commercial sex work,
while one speculated that women are likely to be less assert-
ive in accessing benefits they are entitled to, particularly in a
context increasingly hostile to claimants. One service man-
ager went as far as to state that poverty was the single big-
gest explanatory factor in the rise in DRDs in recent years.
Several of the women with lived experience interviewed
had had benefits withheld or cut, largely as a result of miss-
ing appointments. In one case poor mental health was expli-
citly cited as the cause of loss of entitlements, reflecting
challenges for this population in navigating the complexity
of the social security system:
I’ve not been sanctioned, I was on DLA [Disability Living
Allowance] due to my mental health, and because I’d relapsed
and not picked up my medication, and not kept appointments, I
never renewed the forms, so my benefits got cut in December,
after them overpaying me for 7 months, and I’ve been told that I
have to pay that back, and I don’t feel that’s my mistake, because
I wasn’t made aware of it.
Another explanation raised by stakeholders was a
hypothesized increase in homelessness among people who
use drugs. However, data from NESI suggest no clear trend
over time, overall or by gender, in the prevalence of home-
lessness among people attending injecting equipment provi-
sion outlets in Scotland (Health Protection Scotland &
Glasgow Caledonian University, 2019). Similarly, data from
NDRDD suggests no clear trend for either gender in the per-
centage of decedents who were homeless or living in tem-
porary accommodation at the time of death (Information
Services Division Scotland, 2018a). Although there appears to
have been an increase in recent years in the percentage of
decedents who had been in contact with homelessness serv-
ices in the six months before death, this trend was similar by
gender (Information Services Division Scotland, 2018a).
Conclusions
The question of what might explain the disproportionate rise
in DRDs among women in Scotland is methodologically chal-
lenging, given the limitations of the data and the complexity
of the phenomenon. Any explanation must involve multiple
interacting factors. Figure 6 provides a simplified visual sum-
mary of our understanding to date, illustrating recent trends
and their potential interaction with existing contextual fac-
tors which affect women’s experience of drug use.
This study has a number of strengths: it triangulates mul-
tiple sources (routine data, engagement with professional
stakeholders, and interviews with women who use drugs),
with a thematic matrix used to combine insights across
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different data sources in a systematic way. This enabled us to
propose an integrated explanatory framework which can be
applied and tested in future work. Its limitations reflect those
of the included data sources, most of which rely heavily on
people in contact with services or known to have experi-
enced harms. These data sources also utilize the definition of
DRD used in UK national statistics, which is designed to iden-
tify deaths associated with acute drug use and will exclude
some deaths resulting from indirect or longer-term effects of
drug use and other causes of mortality among people who
use drugs (such as injecting-related infections or external
causes such as accidents, assaults, and some suicides).
Future work to strengthen the evidence base in this area
should focus on collecting or linking longitudinal data on
rates and risk factors for drug-related and all-cause mortality
among community-based cohorts of people who use drugs,
with stratification by gender. This work could also include an
investigation of the role of prescribable drugs. There is also a
need for more in-depth qualitative research on gender in
relation to drug-related death risk: in particular, the impact of
welfare reform and public sector austerity, missed opportuni-
ties among people in treatment, and gendered aspects of
naloxone supply and overdose response. Other areas identi-
fied for further research include an investigation of poten-
tially ‘hidden’ populations of people who use drugs and the
relationship between child protection proceedings and drug-
related harms.
Although evaluating potential policy responses was not
within the scope of the project, some implications can be
drawn from this work. Our findings indicate important diver-
gences in women’s experience of drug-related death risk,
which suggest an important role for ‘gender mainstreaming’
for drug policy, practice, surveillance, and research (European
Institute for Gender Equality, 2017). Such a response should
identify where gender-sensitive approaches may be beneficial
whilst recognising commonalities between genders and the
diversity of experience and needs within them (Wincup,
2016), as well as addressing the intersections between gen-
der and other forms of inequality, such as poverty (European
Monitoring Centre for Drugs & Drug Addiction, 2017).
Our results also highlight the importance of involving
women with lived experience in the design, delivery and
evaluation of policy and services, recognizing that wider
efforts to engage and empower people who use drugs have
not always succeeded in reflecting the diversity of the popu-
lation. Other implications identified by participants included
the need for: more co-ordinated and holistic approaches
across substance use treatment, mental health, physical
health, and social support; trauma-informed and psychologic-
ally-informed services; child- and family-sensitive treatment
services and support for family relationships; greater provi-
sion of employability, education, and volunteering opportuni-
ties; strategies to mitigate the adverse impacts of welfare
reform; and efforts to address the universal problem of
stigma and marginalization among people who use drugs.
Assessing the impact and relative importance of these poten-
tial policy responses should be a priority for future participa-
tory work involving people with lived experience,
practitioners, policymakers, and researchers.
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